09/21/23 4:10 PMNasdaq : PBYI clinical trialPuma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung CancerPuma Biotechnology, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients with small cell lung cancer. The FDA grants Orphan Drug Designation to investigational...RHEA-AIpositive
08/31/23 4:07 PMNasdaq : PBYI conferencesPuma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePuma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the hybrid H.C. Wainwright 25 th Annual Global Investment Conference, which will be held September 11-13, 2023. Neratinib, oral was approved by the U.S. Food and Drug...RHEA-AIvery positive
08/08/23 8:30 AMNasdaq : PBYI clinical trialPuma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung CancerPuma Biotechnology, Inc., a biopharmaceutical company, has been notified by the U.S. Food and Drug Administration that its Investigational New Drug submission has been reviewed, and Puma can proceed with the clinical development of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer. Puma’ s Phase II trial will...RHEA-AIpositive
08/03/23 4:05 PMNasdaq : PBYI earningsPuma Biotechnology Reports Second Quarter Financial ResultsBased on accounting principles generally accepted in the United States, Puma reported net income of $2.1 million, or $0.05 per basic and diluted share, for the second quarter of 2023, compared to net income of $9.4 million, or $0.21 per basic and diluted share, for the second quarter of 2022. Net income for the first six months of 2023 was $3.5 million, or $0.08 per...RHEA-AIneutral
07/20/23 4:15 PMNasdaq : PBYI conferencesearningsPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial ResultsPuma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4: 30 p.m. EDT on Thursday, August 3, 2023, following the release of its second quarter 2023 financial results. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage...RHEA-AIvery positive
06/06/23 5:03 PMNasdaq : PBYI Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 2, 2023, the Compensation Committee of Puma’ s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’ s 2017 Employment Inducement...RHEA-AIvery positive
06/04/23 9:00 AMNasdaq : PBYI clinical trialPuma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual MeetingPuma Biotechnology, Inc., a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone in metastatic hormone receptor positive and triple negative breast cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2-6 in Chicago and online.RHEA-AIvery positive
05/05/23 5:15 PMNasdaq : PBYI Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’ s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’ s 2017 Employment Inducement...RHEA-AIvery positive
05/04/23 4:04 PMNasdaq : PBYI earningsPuma Biotechnology Reports First Quarter Financial ResultsProduct revenue, net in the first quarter of 2023 was $46.8 million, compared to product revenue, net of $40.7 million in the first quarter of 2022.. Based on accounting principles generally accepted in the United States, Puma reported net income of $1.4 million, or $0.03 per basic and diluted share, for the first quarter of 2023, compared to net loss of $3.4 million,...RHEA-AIneutral
04/20/23 4:15 PMNasdaq : PBYI conferencesearningsPuma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial ResultsPuma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/ 4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023 financial results. Please dial in at least 10 minutes in advance and inform the operator that you would like to join the“ Puma Biotechnology Conference Call.” A live webcast of the...RHEA-AIneutral